Song Kyung, Wang Hui, Krebs Tracy L, Wang Bingcheng, Kelley Thomas J, Danielpour David
Case Comprehensive Cancer Center Research Laboratories, Division of Pediatric Hematology/Oncology, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Mol Endocrinol. 2010 Oct;24(10):2019-29. doi: 10.1210/me.2010-0165. Epub 2010 Aug 25.
Androgens suppress TGF-β responses in the prostate through mechanisms that are not fully explored. We have recently reported that 5α-dihydrotestosterone (DHT) suppresses the ability of TGF-β to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-β receptor II (ΤβRII). We now show that androgen receptor (AR) activated by DHT suppresses the TGF-β-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TβRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TβRII alone does not fully account for the impact of DHT on TGF-β responses. Instead, we demonstrate that such suppression occurs through loss of total Smad3, resulting from transcriptional suppression of Smad3. We provide evidence that DHT down-regulates the promoter activity of Smad3 in various prostate cancer cell lines, including NRP-154+AR, DU145+AR, LNCaP, and VCaP, at least partly through androgen-dependent inactivation of Sp1. Moreover, we show that overexpression of Smad3 reverses the ability of DHT to protect against TGF-β-induced apoptosis in NRP-154+AR, supporting our model that loss of Smad3 by DHT is involved in the protection against TGF-β-induced apoptosis. Together, these findings suggest that deregulated/enhanced expression and activation of AR in prostate carcinomas may intercept the tumor suppressor function of TGF-β through transcriptional suppression of Smad3, thereby providing new mechanistic insight into the development of castration-resistant prostate cancer.
雄激素通过尚未完全明确的机制抑制前列腺中的转化生长因子-β(TGF-β)反应。我们最近报道,5α-双氢睾酮(DHT)抑制TGF-β抑制前列腺上皮细胞增殖和诱导其凋亡的能力,并提供证据表明这种抑制是由TGF-β受体II(ΤβRII)的转录下调所致。我们现在表明,在巨细胞病毒启动子控制下过表达TβRII的LNCaP细胞中,由DHT激活的雄激素受体(AR)抑制TGF-β诱导的Sma和Mad相关蛋白(Smad)3磷酸化,而该启动子不受DHT调控,这表明仅TβRII的转录抑制并不能完全解释DHT对TGF-β反应的影响。相反,我们证明这种抑制是通过Smad3总量的减少而发生的,这是由于Smad3的转录抑制所致。我们提供证据表明,DHT至少部分通过雄激素依赖的Sp1失活,下调包括NRP-154+AR、DU145+AR、LNCaP和VCaP在内的各种前列腺癌细胞系中Smad3的启动子活性。此外,我们表明Smad3的过表达逆转了DHT在NRP-154+AR中抵御TGF-β诱导凋亡的能力,支持了我们的模型,即DHT导致的Smad3缺失参与了对TGF-β诱导凋亡的抵御。总之,这些发现表明前列腺癌中AR的失调/增强表达和激活可能通过对Smad3的转录抑制来阻断TGF-β的肿瘤抑制功能,从而为去势抵抗性前列腺癌的发展提供了新的机制见解。